PETER MEYERS, CFO of Tetralogic Pharmaceuticals, bought 142,857 shares of Tetralogic (Stock Symbol: TLOG) at $7 per share for a total amount of $1 million on December 17, 2013.
Company Name is located in Malvern, PA.
On December 31st 2013, TetraLogic Pharmaceuticals Corporation (TLOG) announced that the underwriters for its initial public offering of common stock have exercised their option to purchase an additional 1,072,115 shares of common stock at a public offering price of $7.00 per share, before the underwriting discount. The closing of the option exercise occurred on December 31, 2013, resulting in net proceeds to TetraLogic of approximately $6,970,000 after the underwriting discount and offering costs.
According to Capital IQ, Tetralogic has a market cap of $120 million , an enterprise value of $112 million, and trailing 12 month revenues is not meaningful.
TetraLogic Pharmaceuticals Corporation (TetraLogic) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing novel small molecule therapeutics that mimic Second Mitochondrial Activator of Caspases (SMAC)-mimetics, and are designed to cause or enable abnormal cells that are resistant to the body’s immune system to self-destruct. Birinapant, its clinical-stage product candidate, is being tested in Phase I and Phase II oncology clinical trials for multiple solid tumors and hematological malignancies. The Company’s clinical trials of birinapant have enrolled over 275 subjects. The Company’s lead program is colorectal cancer (CRC), where it has substantially completed a Phase I/II clinical trial. TetraLogic’s lead Smac mimetic drug, birinapant (formerly TL32711), is in Phase II clinical trials and is being developed for both solid tumors and hematological malignancies as a single agent and in combination with several standard-of-care cancer therapies.
Mr. Meyers is 44 years old.
According to the biography, Mr. Pete A. Meyers is Chief Financial Officer, Treasurer of Tetralogic Pharmaceuticals Corp. He joined Tetralogic in August 2013 as Chief Financial Officer and was appointed as Treasurer in September 2013. Prior to joining us, Mr. Meyers worked in health care investment banking for 18 years, most recently as Managing Director/Co-Head of Global Health Care Investment Banking at Deutsche Bank Securities Inc., or Deutsche Bank Securities, where he worked in various roles from March 2005 to January 2013. From February 2013 to July 2013, Mr. Meyers took time off to pursue opportunities outside of the investment banking industry. Prior to joining Deutsche Bank Securities in 2005, Mr. Meyers held the position of Managing Director, Health Care Investment Banking, at Credit Suisse LLC. Among other experience, he also served as Vice President, HealthCare Mergers and Acquisitions at Dillon, Read & Co. (and successor firms). Mr. Meyers graduated from Boston College with a B.S. in finance in 1991 and received an MBA from Columbia Business School in 1995.
All stories in DailyStocks.com are for informational purposes only. This is NOT a stock recommendation. This DailyStocks.com story is a daily light analysis featuring a stock with insider buying. With some caveats, insiders purchase a stock because they think the stock is going up. There are other factors to consider such as size of the transaction relative to their compensation and net worth. Sometimes, insiders might be propping a stock price up for future financing. Sometimes, the amount of insider buying are misread or misreported. Each month, DailyStocks releases a a summary of the stocks with insider buying. Sign up for the free monthly newsletter at DailyStocks.com .
About Dailystocks.com: DailyStocks.com is the place where you can find stories about stocks with insider buying, where you can educate yourself about stock market investing, and where you can perform the stock search engine analysis – you enter a stock symbol, and you get a resulting page of stock ticker indexed links so that you do not have to type the stock symbol each time.
Recent Comments